Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING; (2) ELECTION OF DIRECTORS FOR THE THIRD SESSION OF THE BOARD; (3) ELECTION OF THE EMPLOYEE REPRESENTATIVE DIRECTOR; AND (4) THE CHAIRMAN OF THE BOARD, THE CHIEF EXECUTIVE OFFICER OF THE COMPANY AND THE COMPOSITION OF THE BOARD COMMITTEES

Reference is made to the circular (the "**Circular**") of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司(the "**Company**") incorporating, amongst others, the notice of 2025 annual general meeting (the "**AGM**") dated May 21, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

1. POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

ATTENDANCE AT THE AGM

The Board is pleased to announce that the AGM was held at Room 6134, Phase III Building of the Company at 58 Middle Beijing Road, Yantai Development Zone, Yantai Area of Shandong Pilot Free Trade Zone, PRC on Tuesday, June 16, 2026 at 2:00 p.m.

The attendance of the AGM was as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against resolutions)	Number of Shares present (in person or by proxy)	Approximate % of Shares present (in person or by proxy)
A Shares	355,896,244	203,730,892	36.0919%
H Shares	208,581,239	30,542,352	5.4107%
Total	**564,477,483**	**234,273,244**	**41.5027%**

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

The AGM was convened by the Board. All Directors attended the AGM.

POLL RESULTS OF THE AGM

The poll results of the AGM were as follows:

Ordinary Resolutions		Number of votes and percentage of the total voting Shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the report on the work of the board of directors of the Company for the year 2025.	234,136,735 99.9417%	56,369 0.0241%	80,140 0.0342%	Yes
2.	To consider and approve the financial accounts report of the Company for the year 2025.	234,136,735 99.9417%	56,369 0.0241%	80,140 0.0342%	Yes
3.	To consider and approve the full text of annual report of the Company for the year 2025 and its summary.	234,136,735 99.9417%	56,369 0.0241%	80,140 0.0342%	Yes
4.	To consider and approve the annual profit distribution plan of the Company for the year 2025.	234,196,433 99.9672%	57,926 0.0247%	18,885 0.0081%	Yes
5.	To consider and approve the re-appointment of 2026 domestic and foreign accounting firms.	233,681,635 99.7475%	575,469 0.2456%	16,140 0.0069%	Yes
6.	To consider and confirm the remuneration of Directors of the Company.	234,196,113 99.9671%	61,591 0.0263%	15,540 0.0066%	Yes

Special Resolutions		Number of votes and percentage of the total voting Shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
7.	To consider and approve the general mandate to issue additional shares of the Company.	209,813,494 89.5593%	24,444,210 10.4341%	15,540 0.0066%	Yes
8.	To consider and approve the change of the registered capital of the Company and the proposed amendments to the Articles of Association of the Company.	234,196,713 99.9673%	55,991 0.0239%	20,540 0.0088%	Yes
Ordinary Resolutions		**Number of votes and percentage of the total voting Shares at the AGM**			**Passed by Shareholders**
		For	**Against**	**Abstain**	
9.	To consider and approve the proposed amendments to and formulation of certain internal management policies of the Company:				
	9.1 To amend the Rules of Procedures for the Board of Directors.	234,195,659 99.9669%	35,513 0.0152%	42,072 0.0180%	Yes
	9.2 To formulate the Remuneration Management Policy for Directors and Senior Management Personnel.	234,169,881 99.9559%	61,291 0.0262%	42,072 0.0180%	Yes
10.	To consider and approve the proposed change of certain sub-projects and the amount adjustments under the A Share Offering proceeds-funded projects.	234,201,113 99.9692%	55,991 0.0239%	16,140 0.0069%	Yes

Ordinary Resolutions (Cumulative Voting)		Number of votes and percentage of the total voting Shares at the AGM	Passed by Shareholders
11.	To consider and approve the election of Directors (other than Independent Non-executive Directors) for the Third Session of the Board:		
	11.1 To elect Mr. Wang Weidong as an executive Director of the Company.	230,988,671 98.5980%	Yes
	11.2 To elect Dr. Fang Jianmin as an executive Director of the Company.	231,768,204 98.9307%	Yes
	11.3 To elect Mr. Wen Qingkai as an executive Director of the Company.	231,621,203 98.8680%	Yes
	11.4 To elect Dr. Wang Liqiang as a non-executive Director of the Company.	228,214,074 97.4136%	Yes
	11.5 To elect Ms. Fang Michelle Yi as an executive Director of the Company.	231,731,167 98.9149%	Yes
12.	To consider and approve the election of Independent Non-executive Directors for the Third Session of the Board:		
	12.1 To elect Mr. Song Xiliang as an independent non-executive Director of the Company.	233,944,684 99.8598%	Yes
	12.2 To elect Mr. Huang Guobin as an independent non-executive Director of the Company.	229,681,887 98.0402%	Yes
	12.3 To elect Mr. Chen Yunjin as an independent non-executive Director of the Company.	233,739,397 99.7721%	Yes

As more than half of the votes casted in favour of the above ordinary resolutions numbered 1 to 6 and 9 to 12, these resolutions were duly passed.

As not less than two-thirds of the votes casted in favour of the above special resolutions numbered 7 to 8, these resolutions were duly passed.

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. Two representatives of the Shareholders and two lawyers of King & Wood Mallesons participated in the scrutiny of the poll results.

2. ELECTION OF DIRECTORS FOR THE THIRD SESSION OF THE BOARD

The Board is pleased to announce that, at the AGM, (1) Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Ms. Fang Michelle Yi were elected or re-elected as executive Directors for the third session of the Board; (2) Dr. Wang Liqiang was re-elected as a non-executive Director for the third session of the Board; and (3) Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin were elected or re-elected as independent non-executive Directors for the third session of the Board.

The eight Directors above, together with the employee representative Director, Mr. Wang Yuxiao (王玉曉) ("**Mr. Wang**") whose election and details are set out below, form the third session of the Board. For biographical details and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules in relation to the Directors for the third session of the Board other than Mr. Wang, please refer to the Circular. The term of office of the Directors of the third session of the Board commences from the date of the AGM for three years and up to the expiration of the term of the third session of the Board.

3. ELECTION OF THE EMPLOYEE REPRESENTATIVE DIRECTOR

The Board hereby announces that, in accordance with the relevant requirements of the Company Law, and other laws, regulations, regulatory documents, regulatory rules and listing rules of the jurisdictions where the Company's shares are listed as well as the Articles of Association, the Company shall have one employee representative Director, who shall be elected by the employees' representative assembly and shall not be subject to the approval of the Shareholders' meeting.

The Company held an employees' representative assembly on June 16, 2026, at which, following a democratic election, Mr. Wang was elected as an employee representative Director (executive Director) for the third session of the Board. The term of office of Mr. Wang shall commence from the date of the AGM for three years and up to the expiration of the term of the third session of the Board.

The Company will enter into a service contract with Mr. Wang, and his term of office will commence on the date of the AGM and end on the expiry of the term of the third session of the Board. At the expiry of such term of office, the term is renewable upon re-election. Pursuant to the service contract, Mr. Wang will not receive any additional director's fee or remuneration in his capacity as an employee representative Director (executive Director), but will receive corresponding remuneration in accordance with his positions in the Group with reference to, among others, his experience, duties and prevailing market conditions and in accordance with applicable laws and regulations and the relevant remuneration policies of the Company.

The biographical details of Mr. Wang are as follows:

Mr. Wang, aged 38, has been serving as the vice president of the operations and international cooperation department of the Company since January 2023, responsible for operations, strategic management, international cooperation, competitive intelligence and digital and intelligent innovation of the Company. He was the director of the international cooperation department of the Company from June 2017 to January 2023, responsible for international registration and business development. He was the project director of the Company from December 2014 to June 2017, responsible for international registration.

Mr. Wang obtained a bachelor's degree in managerial economics/human physiology from the University of California, Davis in the United States in September 2013, and is currently pursuing an executive master of business administration degree at Peking University in the PRC.

As at the date of this announcement, the interests of Mr. Wang in the Shares, underlying Shares or debentures of the Company within the meaning of Part XV of the SFO are set out below:

	Nature of interest	**Number of Shares or underlying Shares**	**Approximate percentage in relevant class of Shares[(1)]**	**Approximate percentage of shareholding[(1)]**
Mr. Wang[(2)(3)(4)]	Interests of controlled corporation	192,997,276 A Shares	54.23%	34.19%
	Other	84,400 A Shares	0.02%	0.01%
	Interests of controlled corporation	22,216,551 H Shares	10.65%	3.94%
	Beneficiary of a trust (other than a discretionary interest)	64,400 H Shares	0.03%	0.01%
	Beneficial owner	46,600 H Shares	0.02%	0.01%

Notes:

(1) The calculation is based on percentage of shareholding in a total of 564,477,483 Shares, which consists of 208,581,239 H Shares and 355,896,244 A Shares (including treasury shares of the Company), as at the date of this announcement.

(2) RongChang Holding Group LTD. was a company incorporated in the British Virgin Islands. Mr. Wang controlled more than one-third of the voting power thereof. As such, under the SFO, Mr. Wang is deemed to be interested in the equity interests in which RongChang Holding Group LTD. is interested.

On April 16, 2020, Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian, Dr. Wang Liqiang, Mr. Wang Xudong, Mr. Deng Yong, Mr. Xiong Xiaobin, Mr. Wen Qingkai, Ms. Yang Minhua, Mr. Wei Jianliang, Yantai Rongda Venture Capital Center (Limited Partnership), RongChang Holding Group LTD. and I-NOVA Limited entered into a concert party agreement to confirm that they have acted in concert in the management, decision-making and all major decisions of the Group. As such, each of them is deemed to be interested in the Shares each other is interested in.

(3) As of the date of this announcement, Mr. Wang was granted restricted Shares under the 2022 A Share Scheme and the 2023 A Share Scheme with attribution conditions attached thereto, and Mr. Wang was granted award Shares under the Second H Share Award and Trust Scheme with vesting criteria and conditions attached thereto. As such, under the SFO, Mr. Wang is deemed to be interested in the equity interests underlying the aforesaid restricted Shares and/or award Shares.

(4) Mr. Wang is the son of Mr. Wang Weidong, an executive Director and one of the controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Wang has confirmed that (i) he does not hold any other position with the Company or other members of the Group; (ii) he does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) he has no relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; and (iv) he does not have any interest in the Shares, underlying Shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Wang has confirmed that (i) there is no other information in relation to his appointment which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules; and (ii) there is no other matter in relation to his appointment that needs to be brought to the attention of the Shareholders.

4. THE CHAIRMAN OF THE BOARD, THE CHIEF EXECUTIVE OFFICER OF THE COMPANY AND THE COMPOSITION OF THE BOARD COMMITTEES

The Board hereby announces that, at the first meeting held by the third session of the Board on June 16, 2026, it was resolved that (1) Mr. Wang Weidong has been re-elected as the chairman of the third session of the Board; and (2) Dr. Fang Jianmin has been re-elected as the chief executive officer of the Company, in each case for a term of office commencing from the date of the AGM for three years and up to the expiration of the term of the third session of the Board.

The Board hereby announces that, at the first meeting held by the third session of the Board on June 16, 2026, it was further resolved that the composition of the Board committees of the third session of the Board be as follows:

(1) Audit Committee: Mr. Song Xiliang (Chairman), Mr. Wen Qingkai and Mr. Chen Yunjin;

(2) Remuneration and Appraisal Committee: Mr. Chen Yunjin (Chairman), Mr. Wang Yuxiao and Mr. Song Xiliang;

(3) Nomination Committee: Mr. Huang Guobin (Chairman), Ms. Fang Michelle Yi and Mr. Song Xiliang; and

(4) Strategy Committee: Dr. Fang Jianmin (Chairman), Mr. Wang Weidong and Mr. Huang Guobin,

in each case for a term of office commencing from the date of the AGM for three years and up to the expiration of the term of the third session of the Board.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The PRC
June 16, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr. Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin as the independent non-executive Directors.

* *For identification purpose only*